Get started
Author

Yi Liu

Principal stratum strategy: Potential role in drug development
2021 · Björn Bornkamp, Kaspar Rufibach, et al. · Pharmaceutical Statistics · 68
PDF
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials
2024 · Jonathan I. Silverberg, David Rosmarin, et al. · Nature Communications · 55
PDF
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework
2020 · Evgeny Degtyarev, Kaspar Rufibach, et al. · Statistics in Biopharmaceutical Research · 31
PDF
Sample size and power for the weighted log‐rank test and Kaplan‐Meier based tests with allowance for nonproportional hazards
2019 · Godwin Yung, Yi Liu · Biometrics · 29
Variable Selection with ABC Bayesian Forests
2021 · Yi Liu, Veronika Ročková, et al. · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 25
PDF
Pseudo maximum likelihood estimation for the Cox model with doubly truncated data
2017 · Pao-sheng Shen, Yi Liu · Statistical Papers · 22
Testing for Efficacy in Primary and Secondary Endpoints by Partitioning Decision Paths
2009 · Yi Liu, Jason Hsu · Journal of the American Statistical Association · 20
PDF
Correct and logical causal inference for binary and time‐to‐event outcomes in randomized controlled trials
2021 · Yi Liu, Bushi Wang, et al. · Biometrical Journal · 17
Partition testing in dose–response studies with multiple endpoints
2007 · Yi Liu, Jason Hsu, et al. · Pharmaceutical Statistics · 16
A flexible joint model for multiple longitudinal biomarkers and a time‐to‐event outcome: With applications to dynamic prediction using highly correlated biomarkers
2021 · Ning Li, Yi Liu, et al. · Biometrical Journal · 15
Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents
2020 · Caroline M. Kopruszinski, Juliana Swiokla, et al. · Cellular and Molecular Neurobiology · 10
A new joint screening method for right-censored time-to-event data with ultra-high dimensional covariates
2019 · Yi Liu, Xiaolin Chen, et al. · Statistical Methods in Medical Research · 10
Pseudo MLE for semiparametric transformation model with doubly truncated data
2019 · Pao-sheng Shen, Yi Liu · Journal of the Korean Statistical Society · 10
Adaptive Endpoints Selection with Application in Rare Disease
2023 · Heng Xu, Yi Liu, et al. · Statistics in Biopharmaceutical Research · 9
Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients
2022 · Robert A. Beckman, Zoran Antonijevic, et al. · Pediatric Drugs · 8
Sample size re-estimation for pivotal clinical trials
2020 · Yi Liu, Heng Xu · Contemporary Clinical Trials · 7
Testing multiple primary endpoints in clinical trials with sample size adaptation
2015 · Yi Liu, Mingxiu Hu · Pharmaceutical Statistics · 7
From Logic-Respecting Efficacy Estimands to Logic-Ensuring Analysis Principle for Time-to-Event Endpoint in Randomized Clinical Trials with Subgroups
2023 · Yi Liu, Miao Yang, et al. · Statistics in Biopharmaceutical Research · 6
The fused Kolmogorov–Smirnov screening for ultra-high dimensional semi-competing risks data
2021 · Yi Liu, Xiaolin Chen, et al. · Applied Mathematical Modelling · 6
Model-free feature screening for ultra-high dimensional competing risks data
2020 · Xiaolin Chen, Yahui Zhang, et al. · Statistics & Probability Letters · 5
Thresholding of a Continuous Companion Diagnostic Test Confident of Efficacy in Targeted Population
2016 · Yi Liu, Szu-Yu Tang, et al. · Statistics in Biopharmaceutical Research · 5
Principles of Conditionality and Layering of Error Rates with Application to Platform Trials
2023 · Cui, Xinping, Ouyang, Emily, et al. · arXiv (Cornell University) · 4
PDF
Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS)
2018 · Zhaoyang Teng, Liang Liang, et al. · Statistics in Medicine · 4
Analysis of transformation models with right-truncated data
2016 · Pao-sheng Shen, Yi Liu, et al. · Statistics · 4
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2024 · Sairah Ahmed, John F. DiPersio, et al. · Blood · 3
PDF
Works count: 51
Citation count: 421
H-index: 10
I10-index: 13
Year
Topic
Type